1/12/2022 : 40th Annual J.P. Morgan Healthcare Conference
Alcon 5/11/2022 : Alcon’s First Quarter 2022 Earnings Conference Call
Alcon 8/10/2022 : Alcon’s Second Quarter 2022 Earnings Conference Call
Alcon 11/16/2022 : Alcon’s Third Quarter 2022 Earnings Conference Call
Alcon 11/16/2022 : Alcon’s Third Quarter 2022 Earnings Conference Call
Sandoz News Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Ad hoc announcement pursuant to Art. 53 LR
- Q3 net sales grew +5% (cc¹, +6% USD)
- Innovative Medicines grew +7% (cc, +8% USD)
- Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zolgensma (+28% cc), Promacta/Revolade (+18% cc) and Kisqali (+27% cc)
- Sandoz declined -2% (cc, -1% USD), affected by continued pricing pressures. Ex-US sales grew …
Sandoz News Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
- At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia
- New agreement follows earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland
Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding …
Sandoz News Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
- Sandoz gains rights to three established brands sold in more than 100 markets
- Transaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporins
- Acquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network
Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.
…
Novartis News Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
- Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)
- Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile1
- Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia